News

DBS Effective in Early-Onset Form of Dystonia


 

CHICAGO – The efficacy of deep brain stimulation can be maintained for up to 10 years in DYT1 dystonia, according to data from a study in 26 consecutive patients.

This prospective study is the first to report on more than 3 years of follow-up of deep brain stimulation (DBS) in DYT1 dystonia–a form of primary dystonia that typically presents in early childhood and is caused by a mutation in the DYT1 gene.

Significant decreases in Burke-Fahn-Marsden dystonia rating scale motor and disability scores were observed 1 year after DBS surgery. No significant difference was found when the 1-year scores were compared with the scores at 3, 5, and 6 years for the whole population, Dr. Laura Cif and associates reported in a poster at the 12th International Congress of Parkinson's Disease and Movement Disorders.

Efficacy of DBS therapy was maintained in the two patients who were followed as long as 10 years.

Long-term disease progression is even more important in DYTI dystonia than in other disorders treated with DBS, such as Parkinson's disease, because patients are much younger at the time of surgery and therefore require significantly longer-term follow-up, according to Dr. Cif of the University of Montpellier (France). The age at onset ranged from 6 to 20 years in the study. Moreover, DYT1 dystonia can develop into a life-threatening condition.

Eighteen patients were implanted with a single pair of electrodes in the internal globus pallidus (GPi) and eight patients had a second pair of GPi electrodes implanted because of incomplete initial response or subsequent worsening.

In spite of there being no significant difference 1 year after surgery, a significant difference was observed at 5 years between patients with a single lead vs. those with double leads in motor (8.95 vs. 31.5) and disability (3.61 vs. 7.85) scores. After implantation of additional pairs of leads, only four of the eight patients showed subsequent improvement.

During the follow-up, no patient died, including several patients with status dystonicus, who usually are not expected to survive for more than a few weeks, Dr. Cif said in an interview.

Recommended Reading

Parkinson's Tx May Raise Risk of Impulse Control
MDedge Psychiatry
No Cognitive Benefit Seen for Donepezil
MDedge Psychiatry
Brain Stimulation Tops Medication for Parkinson's
MDedge Psychiatry
Data Watch: Epilepsy-Related Hospital Stays Are on the Rise
MDedge Psychiatry
DBS Improves Tic Severity in Tourette Syndrome Patients
MDedge Psychiatry
Rasagiline Delays Symptoms in Early Parkinson's
MDedge Psychiatry
Selegiline Reduces Some Adverse Events in Parkinson's
MDedge Psychiatry
DBS May Prove Beneficial in Early Parkinson's
MDedge Psychiatry
Double jeopardy: How to treat kids with comorbid anxiety and ADHD
MDedge Psychiatry
ADHD in adults: Matching therapies with patients’ needs
MDedge Psychiatry